Catheter Precision, Inc. announced on May 27, 2025, that it has received CE Mark approval for LockeT, its advanced vascular closure device. This approval signifies compliance with European Union (EU) health, safety, and environmental protection standards.
With the CE Mark, LockeT is now eligible for commercialization in markets within the EU, as well as additional countries including the UK, Switzerland, and Turkey. The European Vascular Closure Devices Market was valued at $3.1 billion in 2024 and is projected to reach $4.3 billion by 2028.
In anticipation of the CE Mark, the company engaged in discussions with distribution partners and received positive feedback from potential LockeT users. Catheter Precision has already received its first order for 100 units from the EU, indicating immediate market interest.
David Jenkins, CEO, stated that this approval is exciting news for the company, as European approvals are becoming increasingly difficult to obtain. He highlighted LockeT's economic advantages for European hospitals, ease of deployment, patient comfort, and intuitive use for recovery nursing.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.